Patent Term Extensions and Filings for Regulatory Exclusivity Periods. Company shall advise Amgen in advance when it is considering any patent term extension or supplementary protection certificates or their equivalents for the Licensed Patents. With respect to any patent listings required for any Regulatory Exclusivity for Products in the Territory, the Parties shall mutually agree on which Licensed Patents to list.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. (a) AKERO will advise AMGEN when it is considering any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents.
(b) Parties will use good faith efforts to mutually agree on (i) which Licensed Patents to list on any patent listings required for any Regulatory Exclusivity for Products or (ii) any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents; provided, that [***].
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. (a) Erasca will advise Katmai if it desires to pursue any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents.
(b) Erasca will apply for an extension of the term of any patent included within the Licensed Patents, if appropriate, under the [***]; provided, however, that such requirement shall not apply if Erasca, acting reasonably and in good faith, determines that seeking an extension of the term for another patent owned or licensed by Erasca would provide a materially longer patent protection coverage for the applicable Licensed Product. If Erasca or its Sublicensee proposes instead to seek an extension of the term for another Patent Right owned or controlled by Erasca, its Affiliate, or its Sublicensee that provides more comprehensive patent protection coverage for the applicable Licensed Product, the Parties will cooperate to request that UC waive any restrictions in the UC License Agreement that would preclude seeking such extension for such other Patent Right, and upon obtaining such waiver from UC, Erasca, or its Affiliate or Sublicensee shall have the right to seek such extension of such Patent Right. Erasca will prepare all documents and Katmai agrees to execute (or request that the UC execute, if applicable) the documents and to take additional action as Erasca reasonably requests in connection therewith. [***] If either Party receives notice pertaining to the Infringement or potential Infringement of any issued patent included with Licensed Patents under the [***] then that Party will within ten (10) days after receipt of such notice of Infringement so notify the other Party.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. RBNC will advise AMGEN when it is considering any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents, Program Patents or Joint Patents. With respect to any patent listings required for any Regulatory Exclusivity for the Products, the Parties will discuss in good faith which Licensed Patents, Joint Patents or Program Patents, if any, to list; provided, the decision as to which Patents are listed resides with RBNC.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. Company shall advise Amgen in advance when it is considering any patent term extension or supplementary protection certificates or their equivalents for the Licensed Patents. Upon Amgen’s request, Company shall provide reasonable cooperation and assistance to Amgen (and/or its licensees) with respect to the preparation and filing of any patent term extension or supplementary protection certificates or their equivalents for the Product in Japan, With respect to any patent listings required for any Regulatory Exclusivity for the Product in the Territory, the Parties shall mutually agree on which Licensed Patents to list.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. BioAge will advise Amgen when it is considering any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents. With respect to any patent listings required for any Regulatory Exclusivity for the Product, the Parties will mutually agree on which Licensed Patents to list.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. (a) XXXXX will advise ONYX when it is considering to file and of any mandatory deadlines with respect to any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents.
(b) Parties will mutually agree on (i) which Licensed Patents to list on any patent listings required for any Regulatory Exclusivity for Products or (ii) any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents. *** = INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
(c) In the event of a dispute between the Parties arising under Section 4.6(b), either Party shall have a right to refer such dispute to the respective Executive Officers and such Executive Officers shall attempt in good faith to resolve such dispute. If the Executive Officers are unable to resolve a given dispute within *** days of the matter being referred to them, then ***.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. (i) Xxxxx will consult with Clovis when considering any patent term restoration or supplemental protection certificates or their equivalent for the Subject Patents. In the event that any election with respect to patent term restoration or supplemental protection certificates or their equivalent for any Subject Patent is available, Xxxxx will decide on whether or not to make any such election, provided that Clovis will have the right to decide whether or not to make any such election with respect to any Specific Patents.
(ii) With respect to any Patent listings required for any Regulatory Exclusivity Periods for Licensed Products, the Parties will mutually agree on which Xxxxx Patents to list.
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. (i) BMS shall have the right, at its costs and expense, subject to consultation with Tranzyme, to pursue any patent term restoration or supplemental protection certificates or their equivalent for the Exclusive Patents. In the event that any election with respect to patent term restoration or supplemental protection certificates or their equivalent for any Exclusive Patent is available based on a Licensed Product, as between the Parties, BMS as the licensee thereof shall have the right to decide whether or not to make any such election.
(ii) With respect to any Patent listings required for any Regulatory Exclusivity Periods for Licensed Products, the Parties shall mutually agree on which Tranzyme Patents to list, provided that (A) BMS shall have the sole right with regards to Exclusive Patents, and (B) BMS shall not be required to list any Patents which, in its sole discretion, it deems to be contrary to Applicable Law (including any applicable consent order or decree to which BMS, its Affiliates or Sublicensee is subject).
Patent Term Extensions and Filings for Regulatory Exclusivity Periods. The Parties will discuss in good faith [***]; provided that [***] (provided, further, that [***]) and [***]. Each filing Party will keep the other Party informed regarding its plans and timelines [***] with respect to Gossamer Patent Rights or Chiesi Patent Rights. The Parties will discuss [***] provided that [***] (provided, further, that [***]) and [***]. The costs incurred in the conduct of activities under this Section 10.6 [***], to be reimbursed at the end of any Calendar Quarter in which such expenses were incurred following the applicable Party’s receipt of an invoice for such amount.
